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Abstract
Background. Recommendations for identifying age-related muscle dysfunction have recently 
been published. We aimed to compare definitions for clinically relevant weakness and low lean 
mass proposed by the Foundation for the National Institutes of Health (FNIH) Sarcopenia project 
with the definition of sarcopenia proposed by the European Working Group on Sarcopenia in Older 
People (EWGSOP).
Methods. A total of 1566 men and women from a British birth cohort had measures of appendicular 
lean mass, grip strength and timed up, and go speed at ages 60–64. Prevalence of low lean 
mass, weakness and slowness, identified using the FNIH and EWGSOP recommendations were 
estimated and compared: using kappa statistics and; by testing cross-sectional associations of both 
definitions of low lean mass and weakness with slowness and self-reported difficulties walking.
Results. The combined prevalence of low lean mass and weakness ranged from 1.1% in men 
using FNIH criteria to 6.4% in women using EWGSOP criteria. There was limited overlap between 
the groups identified using the different criteria, driven by limited agreement between the 
two definitions of low lean mass. Using FNIH criteria, both low lean mass and weakness were 
associated with higher odds of slowness and difficulties walking; whereas low lean mass classified 
using EWGSOP criteria was not associated with these markers of mobility impairment.
Conclusions. At relatively young ages, signs of skeletal muscle function deficit with potential clinical 
relevance are already identifiable in the general population. This suggests that implementation of 
strategies to prevent mobility limitations, related to age-related muscle dysfunction, may need to 
start at least as early as midlife.
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A series of articles recently published outline the findings and recom-
mendations of the Foundation for the National Institutes of Health 
(FNIH) Sarcopenia Project (1–5). This positive initiative helps to 
address some of the key challenges of research on sarcopenia and 
age-related muscle dysfunction which include: (a) identifying clini-
cally meaningful age-related changes in muscle, and the factors 
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across life that drive these changes and; (b) identifying modifiable 
targets for intervention which may reduce the detrimental impact of 
these changes on functional and clinical outcomes. If these and other 
initiatives result in more widely agreed operational definitions for 
what has recently been termed ‘‘skeletal muscle function deficit’’ (6), 
this may offer greater opportunities for evidence synthesis.
In direct response to the call made to evaluate the FNIH recom-
mendations in other study populations (1,4,5), we aimed to use data 
from a nationally representative British birth cohort study (7), to 
compare the definitions for clinically relevant weakness and low lean 
mass proposed by the FNIH (2,3) with the definition of sarcopenia 
proposed by the European Working Group on Sarcopenia in Older 
People (EWGSOP) (8) which is now being applied in a wide range 
of settings (9–11). As mobility impairment has been identified as an 
important primary outcome (1,4) this comparison included tests of 
the associations of low lean mass and weakness with slow walking 
speed and self-reported difficulties walking.
Methods
Study Population
The Medical Research Council National Survey of Health and 
Development (NSHD) is a socially stratified sample of 5362 single-
ton births that took place in one week of March 1946 in mainland 
Britain. Between 2006 and 2010 (at 60–64 years), 2856 eligible study 
members (those known to be alive and living in England, Scotland, 
or Wales) were invited for assessment at one of six clinical research 
facilities (CRFs) or to be visited by a research nurse at home; 2229 
were assessed (1690 at a CRF) (7). Relevant ethical approval was 
obtained and participants provided written consent.
Measures At 60–64 Years
As described in detail elsewhere (12,13), measures of body com-
position (including appendicular lean mass [ALM] [the sum of the 
fat free mass in the limbs excluding bone mineral content]) were 
obtained for study participants who attended a CRF, in the supine 
position using a QDR 4500 Discovery DXA scanner (Hologic Inc, 
Bedford, MA).
Strength and physical performance were assessed by trained 
nurses during the CRF or home visit using standardized proto-
cols. Grip strength (kg) was assessed using an electronic handgrip 
dynamometer (14). Three values were recorded for each hand; then 
the highest was used in analyses. Walking speed was assessed using 
the timed-up and go (TUG) test, with participants instructed to rise 
from a chair, walk 3 m at a normal pace, turn around, return to the 
chair, and sit down. The time taken to complete the test was recorded 
and the speed (m/s) calculated. Participants were also asked whether 
they had difficulty walking for quarter of a mile on the level because 
of long-term health problems. Height and weight were measured and 
used to calculate body mass index (BMI;kg/m2).
Analyses
After deriving the variables required (ie ALM adjusted for height2, 
ALM:BMI ratio, and walking speed, by multiplying TUG speed by 
1.62, based on comparisons of TUG and walking speeds in other 
British study populations with both measures [15]), the FNIH and 
EWGSOP cut-points for low lean mass, weakness and slowness 
were applied. Those participants in the potential analytic sample, 
who were unable to complete the grip strength (n = 17) or TUG 
(n = 8) assessment for health reasons (which included arthritis, other 
musculoskeletal conditions, and cardiorespiratory problems), were 
categorised as weak and slow, respectively.
Prevalence estimates of low lean mass, weakness, slowness, and 
the combinations of these outcomes were calculated. Cohen’s kappa 
was used to compare the different definitions. Logistic regression 
was used to estimate the odds ratios of slowness and self-reported 
difficulty walking associated with the different definitions of low 
lean mass and weakness. Gender-specific analyses were conducted 
on the sample with complete data on lean mass, grip strength, and 
walking speed (n = 1566). Sensitivity analyses, conducted to test the 
impact of including those people unable to perform the grip strength 
and TUG assessments in the main analyses and to assess the robust-
ness of findings, are described in Appendix 1.
Results
To aid comparison with similar estimates in other studies, baseline 
characteristics of the sample included in analyses are presented in 
Appendix 2. Prevalence estimates of low lean mass, weakness and 
slowness, and the combinations of these outcomes are shown in 
Table 1. Estimates of each of these three outcomes alone were much 
higher than combinations of these outcomes, reflecting limited over-
lap (see Appendix 3). As the FNIH criteria are more restrictive (5), 
prevalence estimates using these criteria were slightly lower than 
those using EWGSOP criteria.
There was limited overlap between the groups identified as hav-
ing both low lean mass and weakness using the different criteria 
(Ҡ = .23 in men, .09 in women), driven by limited agreement 
between the two definitions of low lean mass (Ҡ = .10 in men, .02 
in women); 31.6% of men and 40.5% of women had low lean mass 
according to at least one definition, but only 4.8% of men and 5.0% 
of women were identified by both definitions.
Table  1. Prevalence Estimates (%) of Low Lean Mass, Weakness 
and Slowness Identified Using FNIH (1) and EWGSOP (8) Criteria 
(n = 747 men, 819 women)
FNIH EWGSOP
Men Women Men Women
Low lean mass 15.7 14.9 20.8 30.7
Weakness 4.0 6.4 7.5 18.2
Slowness 9.0 9.7 9.0 9.7
Weakness and low lean mass 1.1 2.0 2.3 6.4
(Slowness or weakness) and  
low lean mass
3.1 2.7 4.4 7.3
Slowness and weakness and  
low lean mass
0.3 0.7 0 0.9
Cut-points:
Low lean mass (applied to ALM:BMI ratio for FNIH and ALM/ht2 for 
EWGSOP):
FNIH: Men < 0.789; women < 0.512.
EWGSOP: Men ≤ 7.23 kg/m2; women ≤ 5.67 kg/m2.
Weakness (applied to grip strength):
FNIH: Men < 26 kg; women < 16 kg.
EWGSOP: Men < 30 kg; women < 20 kg.
Slowness (applied to TUG speed after conversion to walking speed):
FNIH and EWGSOP: ≤0.8 m/s.
ALM, appendicular lean mass; BMI, body mass index; EWGSOP, Euro-
pean Working Group on Sarcopenia in Older People; FNIH, Foundation for 
the National Institutes of Health; TUG, timed-up and go test.
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Using the FNIH criteria, low lean mass and weakness were both 
associated with higher odds of slowness and self-reported difficul-
ties walking (Table 2). Low lean mass classified using the EWGSOP 
criteria was not associated with mobility limitation.
Findings from sensitivity analyses suggested that there was no major 
impact on findings of including those people unable to complete the 
grip strength and TUG assessments for health reasons (Appendix 1).
Discussion
In a nationally representative British birth cohort study, assessed in 
early old age, between 2.7% and 7.3% of the population were identi-
fied as having both low lean mass and either weakness or slowness 
according to two sets of recently published criteria (FNIH: 3.1% of 
men, 2.7% of women; EWGSOP: 4.4% of men, 7.3% of women) 
(1,8). Both definitions of weakness and the FNIH definition of low 
lean mass were strongly associated with slowness and self-reported 
difficulties walking. Despite producing lower prevalence estimates of 
low lean mass and weakness, the FNIH definitions were more strongly 
associated with mobility limitations than the EWGSOP definitions.
These analyses respond to the call to evaluate recently proposed 
criteria for the identification of clinically meaningful age-related 
changes in muscle mass, strength, and performance in other study 
populations (1,4,5). While the focus of existing research has been 
on populations aged 65 years and older (often with a mean age of 
70 or older), our analyses of the NSHD at ages 60–64 highlights 
that at relatively young ages, signs of skeletal muscle function deficit 
with potential clinical relevance are already present in the general 
population; reflected in the finding of strong associations of weak-
ness and low lean mass with increased odds of mobility limitation. 
This suggests that there may be opportunities for effective interven-
tion at least as early as midlife to prevent mobility limitations that 
are related to age-related muscle dysfunction.
That some people in a general population in early old age already 
fell below cut-points for low lean mass, weakness and slowness may 
be due to initial developmental differences as well as earlier onset or 
accelerated rates of age-related decline in some individuals. Future 
studies, ideally with longitudinal assessment of muscle from earlier 
in life, should investigate these different pathways which may be 
associated with different health and disability prospects.
That the FNIH definition of low lean mass (which includes 
adjustment for BMI) was associated with slowness and difficulties 
walking; whereas, the EWGSOP definition of low lean mass (which 
includes adjustment for height) was not provided further evidence of 
the need to take account of BMI or fat mass when identifying those 
most likely to have insufficient muscle to support movement. As the 
FNIH definition uses a ratio of ALM to BMI, follow-up work is 
required to identify whether interventions targeting ALM, fat mass, 
or both are most effective in preventing future mobility disability.
This study has a number of major strengths as well as limita-
tions which have recently been discussed in detail elsewhere (12). For 
example, our study population was selected to be nationally repre-
sentative at baseline and remains so in many respects (16). However, 
our main analyses were restricted to those with complete data on 
all three outcomes. As highlighted previously (12), measures of lean 
mass were only attained for those people who underwent a DXA 
assessment during a CRF visit and, as also seen in most other stud-
ies which include detailed clinical assessments of muscle, these par-
ticipants were in better health and less obese than those who were 
visited at home. Our sensitivity analyses (see Appendix 1) suggest 
that this may have led to underestimates of the prevalence of low 
lean mass, weakness and slowness suggesting that the need for ear-
lier intervention may be even greater than our main results suggest.
Lean mass and walking speed were not assessed in the NSHD 
until the most recent data collection, and so we are currently limited 
to cross-sectional analyses of their associations with other outcomes 
alongside our prospective studies of their determinants (12,13). 
However, repeated measures of functional and clinical outcomes 
planned for future waves of data collection will facilitate longitudi-
nal analysis of the consequences of skeletal muscle function deficit.
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Table  2. Odds Ratios of Slowness and Self-reported Difficulties 
Walking by Low Lean Mass and Weakness Identified Using FNIH 
and EWGSOP Criteria
Odds ratio (95% CI) of:
Slowness* Difficulty Walking†
Low lean mass
 FNIH
  Men 2.35 (1.33, 4.17) 3.44 (1.93, 6.11)
  Women 1.80 (1.03, 3.18) 2.59 (1.48, 4.53)
 EWGSOP
  Men 1.22 (0.68, 2.21) 0.77 (0.38, 1.55)
  Women 0.86 (0.51, 1.44) 0.61 (0.34, 1.10)
Weakness
 FNIH
  Men 4.87 (2.13, 11.12) 4.73 (2.01, 11.16)
  Women 3.13 (1.57, 6.26) 5.34 (2.76, 10.33)
 EWGSOP
  Men 3.57 (1.81, 7.04) 2.84 (1.35, 5.97)
  Women 2.63 (1.59, 4.35) 3.10 (1.84, 5.24)
Low lean mass and weakness
 FNIH
  Men 3.46 (0.68, 17.47) 7.30 (1.70, 31.32)
  Women 6.00 (2.12, 16.98) 15.88 (5.71, 44.13)
 EWGSOP
  Men — 0.72 (0.09, 5.54)
  Women 1.50 (0.65, 3.45) 1.81 (0.78, 4.18)
See Table 1 for definitions of low lean mass, weakness and slowness.
*n = 747 men, 819 women.
†n = 745 men, 817 women.
FNIH, Foundation for the National Institutes of Health; EWGSOP, Eur opean 
Working Group on Sarcopenia in Older People.
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